Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Isatuximab with or without Lenalidomide in Treating Patients with High Risk Smoldering Plasma Cell Myeloma

Trial Status: temporarily closed to accrual

This phase II trial studies how well isatuximab with or without lenalidomide works in treating patients with high risk smoldering plasma cell myeloma. Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of the tumor cells to grow and spread. Lenalidomide may help shrink or slow the growth of smoldering plasma cell myeloma. Giving isatuximab and lenalidomide together may help control the disease.